29229 (803)772-7935 2001 Ford Crown Vic 2FAFP71W61X113610 Kinterra Johnson, 5022 Baine St, Cola, SC 29203 2002 Yamaha YZFR1 JYARN10E72A004565 Donald Loehr, 4800 Trenholm Rd, Cola, SC 29206 The owner /lienholder may reclaim vehicle or within fifteen (15) days of this notice by paying to the custodian of the vehicle all charges authorized by law. Additional storage and/or processing costs may be added after the date of this notice. The failure of the owner /lienholder to exercise their right to reclaim the vehicle or within the time provided may be deemed a waiver of all right, title and interest in the vehicle and their consent to sale of the vehicle at public auction. Sale will take place on the first Monday of the month following the expiration of 30 days from the date of this notice "the following businesses" will apply to the Richland/Lexington Magistrates. Public sale will take place at the business of the custodian of the vehicle at 10 O'clock AM.
UNCLAIMED VEHICLES/ PUBLIC SALE The following vehicle are subject to towing, repair and/ or storage liens: are declared to be abandoned pursuant to Section 56-5- 5810, 56-6-5635 and/ or 29- 15-10 SC Law as Amended: and are in the custody of Expedient Recovery, 1711 Risley Road, Columbia, SC 29223. 1999 BUICK REGAL GS/GS; VIN# 2G4WF5213X1519016 Owner: Travis Donte Hanley Address: 1031 Bradford Ridge Ln., Columbia, SC 29223. Lien: Carolina Rides LLC., Address: 409 Black Friars Rd., Columbia, SC 29209 The owner/ lien holder may reclaim vehicle within fifteen  days of this notice by paying to the custodian of the vehicle all charges authorized by law. Additional charges and/ or processing cost may be added after the date of this notice. The failure of the owner/ lien holder to exercise their right to reclaim the vehicle within the time provided may be deemed a waiver of all rights, title, and interest in the vehicle and their consent to sale of the vehicle at public auction. Public sale will take place at the business of the custodian of the vehicle at 10 A.M. on the first Monday of the month following the expiration of 30 days from the date of this notice.
RICHLAND The County of Richland vs. Caroline Jones ET AL Patricia J Downing Tonya Miller Owners and/or Parties of Interest in the Mobile Home located at 599 Anders Dr., Columbia, SC 29203 (TMS #14316-01-18) The above mobile home has been declared a public nuisance, and in violation of the Property Maintenance Code of Richland County. You are hereby notified that the mobile home mentioned above has been "Condemned" and Richland County will have the mobile home demolished as soon as possible on or after October 14, 2013. In accordance with the International Property Maintenance Code Section 110 the cost of said demolition and removal shall be charged against the real estate upon which the mobile home is located and shall be a lien upon such real estate. Therefore, pursuant to the 2012 International Property Maintenance Code Section 107, you are hereby notified to remove all personal contents no later than 4:00p.m., October 13, 2013. If the contents of the mobile home are not removed by the date and time set forth above the contents will be considered abandoned and will be disposed of as debris in the demolition process. Any questions can be addressed to Kecia D. Lara, (803) 576-2148.
Auction Date: 24, October 2013 10:00 AM C037B - Betty Rodoson - Household Good, Furniture, Boxes, Appliances, TV's or Stereo Equip. D096 - Catrina Portee - Household Goods, Furniture, Boxes D109 - Leslie Arnold - Household Goods/Furniture D113 - Marlena Corbin - Household Goods D147 - Marlena Corbin - Household Goods, Furniture, Boxes E164 - Tiffany Burns - Household Goods E226 - Meochia Richardson - Household Goods/Furniture E230 - Timothy Sullivan - Household Goods, Furniture, Boxes, TV's or Stereo Equip. E247 - Michelle McKie - Furniture, Boxes, Appliances E260 - Patty Mailly - Household Goods F326 - Titus Jones - Household Goods H518 - Darriel Boykin - Furniture, Boxes, Appliances, TV's or Stereo Equip., Office Furniture, Office Machines/Equip.
October 2013 2:00 PM 1002 - Tasha Jacobs - Household Goods, Furniture, Boxes, Appliances. 1020 - Pauline Everett - Household Goods, Furniture, Boxes, Appliances, TV's or Stereo Equip. 1021 - Dorothy Andrews - Household Goods. 1023 - Zena Jacobs - Household Goods, Furniture, Appliances, TV's or Stereo Equip. 1316 - Joseph L Barnett - Household Goods/Furniture, TV/Stereo Equipment. 2007 - Sherby Archibald - Household Goods, Furniture, Boxes, TV's or Stereo Equip. 2061 - Sherrell Gray - Household Goods, Furniture, Boxes, TV's or Stereo Equip. 2088 - Kiara C Nesbit - Household Goods/Furniture, TV/Stereo Equipment. 4001 - Geneva Dean - Household Goods, Furniture, Boxes, TV's or Stereo Equip, Office Furniture. 4011 - William Whitlock - Household Goods, Furniture. 4055 - Kathy Myers - Household Goods, Boxes, Other:Clothes. 6029 - Toshawn Irvin - Household Goods, Furniture, Boxes, Appliances. 6067 - Brett Wilson - Household Goods, Boxes, TV's or Stereo Equip. 6068 - Brett Wilson - Household Goods, Boxes, TV's or Stereo Equip. 6122 - Matt Coffee - Household Goods/Furniture. 6146 - Kamilah Smith - Household Goods, Furniture, Boxes, Appliances, TV's or Stereo Equip. 6169 - Jeremy Mathrole - Household Goods, Furniture, Boxes, Sporting Goods, Tools, Appliances, TV's or Stereo Equip, Office Furniture, Office Machines/Equip. 6192 - Tanya Davis - Household Goods. 7033 - Robert Evens - Household Goods/Furniture, Tools/Appliances. 8016 - Mattie Sutton - Household Goods, Furniture.
DEFICIENCy WAIVED Regions Bank d/b/a Regions Mortgage, PLAINTIFF, vs. Lydia G. Perkins, Justin Cardwell, and Harbison Community Association, Inc., DEFENDANT(S). F13-02016 TO THE DEFENDANTS, ABOVE NAMED: YOU ARE HEREBY SUMMONED and required to answer the Complaint in the above entitled action, a copy of which is herewith served upon you, and to serve a copy of your answer upon the undersigned at their office, 1300 Pickens Street, Columbia, South Carolina, within thirty (30) days after service hereof upon you, exclusive of the day of such service, and if you fail to answer the Complaint within the time aforesaid or otherwise appear and defend, the Plaintiff, in this action will apply to the Court for the relief demanded in the Complaint, and judgment by default will be rendered against you for the relief demanded in the Complaint. NOTICE IS HEREBY GIVEN that the original Complaint in the above entitled action was filed in the office of the Clerk of Court for Richland County on September 9, 2013.
Demanded Champion Mortgage Company, LLC, Plaintiff(s) vs. Scott Evan Wollman, et al. Defendant(s). TO THE DEFENDANT(S) ABOVE NAMED: YOU ARE HEREBY SUMMONED and required to answer the Complaint in this action, a copy of which is herewith served upon you, and to serve a copy of your Answer on the undersigned at their offices located at 1587 Northeast Expressway, Atlanta, GA 30329, within thirty (30) days after the service thereof, exclusive of the date of service; and if you fail to do so, judgment by default will be rendered against you for the relief demanded in the Complaint.
C/A NO: 13-CP-40-0566 The Bank of New York Mellon f/k/a The Bank of New York, as Trustee for the Certificateholders of the CWABS, Inc., asset-backed Certificates, Series 2007-13, PLAINTIFF, vs. Lori Corley; Borislav Ivanov; South Carolina Department of Revenue; NBSC, a division of Synovus Bank; Arthur R. Ladia; and Linda K. Harp, DEFENDANT(S). TO THE DEFENDANTS ABOVE NAMED: YOU ARE HEREBY SUMMONED and required to answer the Amended Complaint herein, a copy of which is herewith served upon you, or to otherwise appear and defend, and to serve a copy of your Answer to said Complaint upon the subscribers at their office, 4000 Faber Place, Suite 450, P.O. Box 71727, North Charleston, South Carolina, 29415, or to otherwise appear and defend the action pursuant to applicable court rules, within thirty (30) days after service hereof, exclusive of the day of such service; except that the United States of America, if named, shall have sixty (60) days to answer after the service hereof, exclusive of such service; and if you fail to answer the Complaint or otherwise appear and defend within the time aforesaid, the Plaintiff in this action will apply to the Court for relief demanded therein, and judgment by default will be rendered against you for the relief demanded in the Complaint. TO MINOR(S) OVER FOURTEEN YEARS OF AGE, AND/OR TO MINOR(S) UNDER FOURTEEN YEARS OF AGE AND THE PERSON WITH WHOM THE MINOR(S) RESIDE(S) AND/OR TO PERSONS UNDER SOME LEGAL DISABILITY: YOU ARE FURTHER SUMMONED AND NOTIFIED to apply for the appointment of a guardian ad litem within thirty (30) days after the service of this Summons and Notice upon you. If you fail to do so, application for such appointment will be made by the Plaintiff. YOU WILL ALSO TAKE NOTICE that pursuant to Rule 53(b) SCRCP, as amended effective September 1, 2002, the Plaintiff will move for a general Order of Reference to the Master in Equity for Richland County, which Order shall, pursuant to Rule 53(b) of the South Carolina Rules of Civil Procedure, specifically provide that the said Master in Equity is authorized and empowered to enter a final judgment in this action. If there are counterclaims requiring a jury trial, any party may file a demand under rule 38, SCRCP and the case will be returned to the Circuit Court.
County, which Order shall, pursuant to Rule 53(b) of the South Carolina Rules of Civil Procedure, specifically provide that the said Master in Equity is authorized and empowered to enter a final judgment in this action. If there are counterclaims requiring a jury trial, any party may file a demand under rule 38, SCRCP and the case will be returned to the Circuit Court. PLEASE TAKE NOTICE THAT pursuant to the Supreme Court of South Carolina Administrative Order 2011-05-02-01, you may be eligible for foreclosure intervention programs for the purpose of resolving the above-referenced foreclosure action. If you wish to be considered for a foreclosure intervention program, you must contact Finkel Law Firm LLC, 4000 Faber Place Drive, Suite 450 (29405), P.O. Box 71727 (29415), North Charleston, SC 29405, or call (843) 577-5460 within thirty (30) days from the date of this notice. Finkel Law Firm LLC represents the Plaintiff in this action. Our law firm does not represent you and is not authorized to provide you any legal advice. IF YOU FAIL, REFUSE, OR VOLUNTARILY ELECT NOT TO PARTICIPATE IN THIS FORECLOSURE INTERVENTION PROCESS, THE FORECLOSURE MAY PROCEED. NOTICE PURSUANT TO THE FAIR DEBT COLLECTION PRACTICES ACT (15 U.S.C. § 1692 et seq.): This is an attempt to collect a debt and any information you provide will be used for that purpose. However, if you have previously received a discharge from bankruptcy, this message is not and should be construed as an attempt to collect a debt, but only as a requirement pursuant to the administrative order.
C/A NO: 13-CP-40-4876 James B. Nutter & Company, PLAINTIFF, vs. The Estate of Edward S. Bankhead, and any unknown Heirs of The Estate of Edward S. Bankhead; Lee Ruth Bankhead; Jemaine Bankhead; Dennis Pitts; Melvin Pitts; and any other Heirs, Personal Representatives, Successors, Assigns, Spouses, Creditors, and all others claiming any right, title or interest in the real estate known as 508 Antioch Place, Columbia, SC 29209, any adults or persons in the Military Service of the United States of America, being a class designated as John Doe, and any minors or persons under legal disability, being a class designated as Richard Roe; and United States of America, acting by and through its agency, the Secretary of Housing and Urban Development, DEFENDANT(S). TO THE DEFENDANTS ABOVE NAMED: YOU ARE HEREBY SUMMONED and required to answer the Complaint herein, a copy of which is herewith served upon you, or to otherwise appear and defend, and to serve a copy of your Answer to said Complaint upon the subscribers at their office, P.O. Box 71727, North Charleston, South Carolina, 29415, within thirty (30) days after service hereof, exclusive of the day of such service; except that the United States of America, if named, shall have sixty (60) days to answer after the service hereof, exclusive of the day of such service; and if you fail to answer the Complaint within the time aforesaid, or otherwise appear and defend, the Plaintiff in this action will apply to the Court for relief demanded therein, and judgment by default will be rendered against you for the relief demanded in the Complaint. TO THE MINOR(S) OVER FOURTEEN YEARS OF AGE, AND/OR TO MINOR(S) UNDER FOURTEEN YEARS OF AGE AND THE PERSON WITH WHOM THE MINOR(S) RESIDES AND/OR TO PERSONS UNDER SOME LEGAL DISABILITY: YOU ARE FURTHER SUMMONED AND NOTIFIED to apply for the appointment of a guardian ad litem within thirty (30) days after the service of this Summons and Notice upon you. If you fail to do so, application for such appointment will be made by the Plaintiff. YOU WILL ALSO TAKE NOTICE that should you fail to answer the foregoing Summons, the Plaintiff will move for a general Order of Reference to the Master in Equity for Richland, which Order shall, pursuant to Rule 53(b) of the South Carolina Rules of Civil Procedure, specifically provide that the said Master in Equity is authorized and empowered to enter a final judgment in this action.
COMPLAINT NOTICE IS HEREBY GIVEN that the original Complaint in the above entitled action, together with the Summons, was filed in the Office of the Clerk of Court for Richland County on August 19, 2013 at 9:48 a.m.
(Non-Jury) (007191 ) TO THE DEFENDANT ABOVE-NAMED: YOU ARE HEREBY SUMMONED and required to answer the Complaint in this action, a copy of which is herewith served upon you, and to serve a copy of your Answer to the said Complaint on the Plaintiff or its attorney, Thomas H. Brush or J. Chris Lanning, at the office of, Brush & Lanning, P.A., 12-A Carriage Lane, Charleston, South Carolina, 29407, within thirty (30) days after the service hereof, exclusive of the day of such service; and, if you fail to answer the Complaint within the time aforesaid, we will apply to the Court for Default Judgment to be awarded against you. The Defendant, The United States of America, must answer within sixty (60) days after the service hereof, exclusive of the day of such service; and, if you fail to answer the Complaint within the time aforesaid, we will apply to the Court for Default Judgment to be awarded against you. YOU WILL PLEASE TAKE NOTICE that should you fail to answer the foregoing Summons, the Plaintiff will move for a general Order of Reference of this cause to the Master-in-Equity/Special Referee for the aforesaid County which Order shall, pursuant to Rule 53, South Carolina Rules of Civil Procedure, specifically provide that the said Master in-Equity/Special Referee is authorized and empowered to enter final judgment in this case. An appeal from the final judgment entered by the Master in-Equity/Special Referee shall be made directly to the Supreme Court. Dated at Charleston, South Carolina on the 17th day of July, 2013. The original Summons in this Action was filed with the Clerk of Court's Office on July 19, 2013.


text:
using namespace llvm;

#define DEBUG_TYPE "mccodeemitter"

STATISTIC(MCNumEmitted, "Number of MC instructions emitted");
STATISTIC(MCNumFixups, "Number of MC fixups created");

namespace {
class RISCVMCCodeEmitter : public MCCodeEmitter {
  RISCVMCCodeEmitter(const RISCVMCCodeEmitter &) = delete;
  void operator=(const RISCVMCCodeEmitter &) = delete;
  MCContext &Ctx;
  MCInstrInfo const &MCII;

public:
  RISCVMCCodeEmitter(MCContext &ctx, MCInstrInfo const &MCII)
      : Ctx(ctx), MCII(MCII) {}

  ~RISCVMCCodeEmitter() override {}

  void encodeInstruction(const MCInst &MI, raw_ostream &OS,
                         SmallVectorImpl<MCFixup> &Fixups,
                         const MCSubtargetInfo &STI) const override;

  void expandFunctionCall(const MCInst &MI, raw_ostream &OS,
                          SmallVectorImpl<MCFixup> &Fixups,
                          const MCSubtargetInfo &STI) const;

  void expandAddTPRel(const MCInst &MI, raw_ostream &OS,
                      SmallVectorImpl<MCFixup> &Fixups,
                      const MCSubtargetInfo &STI) const;

  /// TableGen'erated function for getting the binary encoding for an
  /// instruction.
  uint64_t getBinaryCodeForInstr(const MCInst &MI,
                                 SmallVectorImpl<MCFixup> &Fixups,
                                 const MCSubtargetInfo &STI) const;

  /// Return binary encoding of operand. If the machine operand requires
  /// relocation, record the relocation and return zero.
  unsigned getMachineOpValue(const MCInst &MI, const MCOperand &MO,
                             SmallVectorImpl<MCFixup> &Fixups,
                             const MCSubtargetInfo &STI) const;

  unsigned getImmOpValueAsr1(const MCInst &MI, unsigned OpNo,
                             SmallVectorImpl<MCFixup> &Fixups,
                             const MCSubtargetInfo &STI) const;

  unsigned getImmOpValue(const MCInst &MI, unsigned OpNo,
                         SmallVectorImpl<MCFixup> &Fixups,
                         const MCSubtargetInfo &STI) const;
};
} // end anonymous namespace

MCCodeEmitter *llvm::createRISCVMCCodeEmitter(const MCInstrInfo &MCII,
                                              const MCRegisterInfo &MRI,
                                              MCContext &Ctx) {
  return new RISCVMCCodeEmitter(Ctx, MCII);
}

// Expand PseudoCALL(Reg), PseudoTAIL and PseudoJump to AUIPC and JALR with
// relocation types. We expand those pseudo-instructions while encoding them,
// meaning AUIPC and JALR won't go through RISCV MC to MC compressed
// instruction transformation. This is acceptable because AUIPC has no 16-bit
// form and C_JALR has no immediate operand field.  We let linker relaxation
// deal with it. When linker relaxation is enabled, AUIPC and JALR have a
// chance to relax to JAL.
// If the C extension is enabled, JAL has a chance relax to C_JAL.
void RISCVMCCodeEmitter::expandFunctionCall(const MCInst &MI, raw_ostream &OS,
                                            SmallVectorImpl<MCFixup> &Fixups,
                                            const MCSubtargetInfo &STI) const {
  MCInst TmpInst;
  MCOperand Func;
  Register Ra;
  if (MI.getOpcode() == RISCV::PseudoTAIL) {
    Func = MI.getOperand(0);
    Ra = RISCV::X6;
  } else if (MI.getOpcode() == RISCV::PseudoCALLReg) {
    Func = MI.getOperand(1);
    Ra = MI.getOperand(0).getReg();
  } else if (MI.getOpcode() == RISCV::PseudoCALL) {
    Func = MI.getOperand(0);
    Ra = RISCV::X1;
  } else if (MI.getOpcode() == RISCV::PseudoJump) {
    Func = MI.getOperand(1);
    Ra = MI.getOperand(0).getReg();
  }
  uint32_t Binary;

  assert(Func.isExpr() && "Expected expression");

  const MCExpr *CallExpr = Func.getExpr();

  // Emit AUIPC Ra, Func with R_RISCV_CALL relocation type.
  TmpInst = MCInstBuilder(RISCV::AUIPC)
                .addReg(Ra)
                .addOperand(MCOperand::createExpr(CallExpr));
  Binary = getBinaryCodeForInstr(TmpInst, Fixups, STI);
  support::endian::write(OS, Binary, support::little);

  if (MI.getOpcode() == RISCV::PseudoTAIL ||
      MI.getOpcode() == RISCV::PseudoJump)
    // Emit JALR X0, Ra, 0
    TmpInst = MCInstBuilder(RISCV::JALR).addReg(RISCV::X0).addReg(Ra).addImm(0);
  else
    // Emit JALR Ra, Ra, 0
    TmpInst = MCInstBuilder(RISCV::JALR).addReg(Ra).addReg(Ra).addImm(0);
  Binary = getBinaryCodeForInstr(TmpInst, Fixups, STI);
  support::endian::write(OS, Binary, support::little);
}

// Expand PseudoAddTPRel to a simple ADD with the correct relocation.
void RISCVMCCodeEmitter::expandAddTPRel(const MCInst &MI, raw_ostream &OS,
                                        SmallVectorImpl<MCFixup> &Fixups,
                                        const MCSubtargetInfo &STI) const {
  MCOperand DestReg = MI.getOperand(0);
  MCOperand SrcReg = MI.getOperand(1);
  MCOperand TPReg = MI.getOperand(2);
  assert(TPReg.isReg() && TPReg.getReg() == RISCV::X4 &&
         "Expected thread pointer as second input to TP-relative add");

  MCOperand SrcSymbol = MI.getOperand(3);
  assert(SrcSymbol.isExpr() &&
         "Expected expression as third input to TP-relative add");

  const RISCVMCExpr *Expr = dyn_cast<RISCVMCExpr>(SrcSymbol.getExpr());
  assert(Expr && Expr->getKind() == RISCVMCExpr::VK_RISCV_TPREL_ADD &&
         "Expected tprel_add relocation on TP-relative symbol");

  // Emit the correct tprel_add relocation for the symbol.
  Fixups.push_back(MCFixup::create(
      0, Expr, MCFixupKind(RISCV::fixup_riscv_tprel_add), MI.getLoc()));

  // Emit fixup_riscv_relax for tprel_add where the relax feature is enabled.
  if (STI.getFeatureBits()[RISCV::FeatureRelax]) {
    const MCConstantExpr *Dummy = MCConstantExpr::create(0, Ctx);
    Fixups.push_back(MCFixup::create(
        0, Dummy, MCFixupKind(RISCV::fixup_riscv_relax), MI.getLoc()));
  }

  // Emit a normal ADD instruction with the given operands.
  MCInst TmpInst = MCInstBuilder(RISCV::ADD)
                       .addOperand(DestReg)
                       .addOperand(SrcReg)
                       .addOperand(TPReg);
  uint32_t Binary = getBinaryCodeForInstr(TmpInst, Fixups, STI);
  support::endian::write(OS, Binary, support::little);
}

void RISCVMCCodeEmitter::encodeInstruction(const MCInst &MI, raw_ostream &OS,
                                           SmallVectorImpl<MCFixup> &Fixups,
                                           const MCSubtargetInfo &STI) const {
  const MCInstrDesc &Desc = MCII.get(MI.getOpcode());
  // Get byte count of instruction.
  unsigned Size = Desc.getSize();

  if (MI.getOpcode() == RISCV::PseudoCALLReg ||
      MI.getOpcode() == RISCV::PseudoCALL ||
      MI.getOpcode() == RISCV::PseudoTAIL ||
      MI.getOpcode() == RISCV::PseudoJump) {
    expandFunctionCall(MI, OS, Fixups, STI);
    MCNumEmitted += 2;
    return;
  }

  if (MI.getOpcode() == RISCV::PseudoAddTPRel) {
    expandAddTPRel(MI, OS, Fixups, STI);
    MCNumEmitted += 1;
    return;
  }

  switch (Size) {
  default:
    llvm_unreachable("Unhandled encodeInstruction length!");
  case 2: {
    uint16_t Bits = getBinaryCodeForInstr(MI, Fixups, STI);
    support::endian::write<uint16_t>(OS, Bits, support::little);
    break;
  }
  case 4: {
    uint32_t Bits = getBinaryCodeForInstr(MI, Fixups, STI);
    support::endian::write(OS, Bits, support::little);
    break;
  }
  }

  ++MCNumEmitted; // Keep track of the # of mi's emitted.
}

unsigned
RISCVMCCodeEmitter::getMachineOpValue(const MCInst &MI, const MCOperand &MO,
                                      SmallVectorImpl<MCFixup> &Fixups,
                                      const MCSubtargetInfo &STI) const {

  if (MO.isReg())
    return Ctx.getRegisterInfo()->getEncodingValue(MO.getReg());

  if (MO.isImm())
    return static_cast<unsigned>(MO.getImm());

  llvm_unreachable("Unhandled expression!");
  return 0;
}

unsigned
RISCVMCCodeEmitter::getImmOpValueAsr1(const MCInst &MI, unsigned OpNo,
                                      SmallVectorImpl<MCFixup> &Fixups,
                                      const MCSubtargetInfo &STI) const {
  const MCOperand &MO = MI.getOperand(OpNo);

  if (MO.isImm()) {
    unsigned Res = MO.getImm();
    assert((Res & 1) == 0 && "LSB is non-zero");
    return Res >> 1;
  }

  return getImmOpValue(MI, OpNo, Fixups, STI);
}

unsigned RISCVMCCodeEmitter::getImmOpValue(const MCInst &MI, unsigned OpNo,
                                           SmallVectorImpl<MCFixup> &Fixups,
                                           const MCSubtargetInfo &STI) const {
  bool EnableRelax = STI.getFeatureBits()[RISCV::FeatureRelax];
  const MCOperand &MO = MI.getOperand(OpNo);

  MCInstrDesc const &Desc = MCII.get(MI.getOpcode());
  unsigned MIFrm = Desc.TSFlags & RISCVII::InstFormatMask;

  // If the destination is an immediate, there is nothing to do.
  if (MO.isImm())
    return MO.getImm();

  assert(MO.isExpr() &&
         "getImmOpValue expects only expressions or immediates");
  const MCExpr *Expr = MO.getExpr();
  MCExpr::ExprKind Kind = Expr->getKind();
  RISCV::Fixups FixupKind = RISCV::fixup_riscv_invalid;
  bool RelaxCandidate = false;
  if (Kind == MCExpr::Target) {
    const RISCVMCExpr *RVExpr = cast<RISCVMCExpr>(Expr);

    switch (RVExpr->getKind()) {
    case RISCVMCExpr::VK_RISCV_None:
    case RISCVMCExpr::VK_RISCV_Invalid:
    case RISCVMCExpr::VK_RISCV_32_PCREL:
      llvm_unreachable("Unhandled fixup kind!");
    case RISCVMCExpr::VK_RISCV_TPREL_ADD:
      // tprel_add is only used to indicate that a relocation should be emitted
      // for an add instruction used in TP-relative addressing. It should not be
      // expanded as if representing an actual instruction operand and so to
      // encounter it here is an error.
      llvm_unreachable(
          "VK_RISCV_TPREL_ADD should not represent an instruction operand");
    case RISCVMCExpr::VK_RISCV_LO:
      if (MIFrm == RISCVII::InstFormatI)
        FixupKind = RISCV::fixup_riscv_lo12_i;
      else if (MIFrm == RISCVII::InstFormatS)
        FixupKind = RISCV::fixup_riscv_lo12_s;
      else
        llvm_unreachable("VK_RISCV_LO used with unexpected instruction format");
      RelaxCandidate = true;
      break;
    case RISCVMCExpr::VK_RISCV_HI:
      FixupKind = RISCV::fixup_riscv_hi20;
      RelaxCandidate = true;
      break;
    case RISCVMCExpr::VK_RISCV_PCREL_LO:
      if (MIFrm == RISCVII::InstFormatI)
        FixupKind = RISCV::fixup_riscv_pcrel_lo12_i;
      else if (MIFrm == RISCVII::InstFormatS)
        FixupKind = RISCV::fixup_riscv_pcrel_lo12_s;
      else
        llvm_unreachable(
            "VK_RISCV_PCREL_LO used with unexpected instruction format");
      RelaxCandidate = true;
      break;
    case RISCVMCExpr::VK_RISCV_PCREL_HI:
      FixupKind = RISCV::fixup_riscv_pcrel_hi20;
      RelaxCandidate = true;
      break;
    case RISCVMCExpr::VK_RISCV_GOT_HI:
      FixupKind = RISCV::fixup_riscv_got_hi20;
      break;
    case RISCVMCExpr::VK_RISCV_TPREL_LO:
      if (MIFrm == RISCVII::InstFormatI)
        FixupKind = RISCV::fixup_riscv_tprel_lo12_i;
      else if (MIFrm == RISCVII::InstFormatS)
        FixupKind = RISCV::fixup_riscv_tprel_lo12_s;
      else
        llvm_unreachable(
            "VK_RISCV_TPREL_LO used with unexpected instruction format");
      RelaxCandidate = true;
      break;
    case RISCVMCExpr::VK_RISCV_TPREL_HI:
      FixupKind = RISCV::fixup_riscv_tprel_hi20;
      RelaxCandidate = true;
      break;
    case RISCVMCExpr::VK_RISCV_TLS_GOT_HI:
      FixupKind = RISCV::fixup_riscv_tls_got_hi20;
      break;
    case RISCVMCExpr::VK_RISCV_TLS_GD_HI:
      FixupKind = RISCV::fixup_riscv_tls_gd_hi20;
      break;
    case RISCVMCExpr::VK_RISCV_CALL:
      FixupKind = RISCV::fixup_riscv_call;
      RelaxCandidate = true;
      break;
    case RISCVMCExpr::VK_RISCV_CALL_PLT:
      FixupKind = RISCV::fixup_riscv_call_plt;
      RelaxCandidate = true;
      break;
    }
  } else if (Kind == MCExpr::SymbolRef &&
             cast<MCSymbolRefExpr>(Expr)->getKind() == MCSymbolRefExpr::VK_None) {
    if (Desc.getOpcode() == RISCV::JAL) {
      FixupKind = RISCV::fixup_riscv_jal;
    } else if (MIFrm == RISCVII::InstFormatB) {
      FixupKind = RISCV::fixup_riscv_branch;
    } else if (MIFrm == RISCVII::InstFormatCJ) {
      FixupKind = RISCV::fixup_riscv_rvc_jump;
    } else if (MIFrm == RISCVII::InstFormatCB) {
      FixupKind = RISCV::fixup_riscv_rvc_branch;
    }
  }

  assert(FixupKind != RISCV::fixup_riscv_invalid && "Unhandled expression!");

  Fixups.push_back(
      MCFixup::create(0, Expr, MCFixupKind(FixupKind), MI.getLoc()));
  ++MCNumFixups;

  // Ensure an R_RISCV_RELAX relocation will be emitted if linker relaxation is
  // enabled and the current fixup will result in a relocation that may be
  // relaxed.
  if (EnableRelax && RelaxCandidate) {
    const MCConstantExpr *Dummy = MCConstantExpr::create(0, Ctx);
    Fixups.push_back(
    MCFixup::create(0, Dummy, MCFixupKind(RISCV::fixup_riscv_relax),
                    MI.getLoc()));
    ++MCNumFixups;
  }

  return 0;
}

#include "RISCVGenMCCodeEmitter.inc"

redpajama_set_name: RedPajamaGithub


text:
module BigMac
  module OS
    puts "Loading OSX"
    class OSX < GenericOS
      class << self
        include Mixin::ShellOut

        def flavor
          osx_codename = codename(shell_out('uname -r').stdout.strip)
          case osx_codename
          when "Mavericks"
            Mavericks.new
          else
            raise "OS X [#{osx_codename}] is not supported. Feel free to submit a pull request."
          end
        end

        def codename(version)
          case version
          when /^13\.\d+\.\d+/
            "Mavericks"
          when /^12\.\d+\.\d+/
            "Mountain Lion"
          when /^11\.\d+\.\d+/
            "Lion"
          else
            "old ass"
          end
        end
      end
    end

    class Mavericks < OSX
      def prerequisites
        [
          BigMac::Prerequisites::Chef.new,
          BigMac::Prerequisites::OSX::Mavericks::CommandLineTools.new,
          BigMac::Prerequisites::Berkshelf.new
        ]
      end
    end
  end
end


FORT LAUDERDALE, FL / ACCESSWIRE / March 11, 2019 / BBX Capital Corporation (NYSE: BBX, OTCQX: BBXTB) ("BBX Capital" or the "Company") reported today its financial results for the quarter and year ended December 31, 2018.
(1) See the supplemental tables included in this release for a reconciliation of BBX Capital's cash flow from operating activities to free cash flow. Free cash flow is defined as cash provided by operating activities less capital expenditures for property and equipment.
(2) See the supplemental tables included in this release for a reconciliation of BBX Capital's net income to adjusted EBITDA.
"The Company recently announced its intention to take Bluegreen Vacations Corporation (NYSE:BXG) ("Bluegreen") private through a statutory short-form merger under Florida law. Each share of Bluegreen's common stock outstanding at the effective time of the merger, other than shares beneficially owned by BBX Capital and shareholders who duly exercise and perfect appraisal rights in accordance with Florida law, would pursuant to the merger be converted into the right to receive $16.00 per share in cash. As a result of the proposed merger, BBX Capital will own 100% of Bluegreen Vacations," commented Alan B. Levan, Chairman and Chief Executive Officer of BBX Capital Corporation.
About BBX Capital Corporation: BBX Capital Corporation (BBX) (BBXTB) is a Florida-based diversified holding company whose principal investments include Bluegreen Vacations Corporation (NYSE:BXG), BBX Capital Real Estate, Renin Holdings, and IT'SUGAR. For additional information, please visit www.BBXCapital.com.
About Bluegreen Vacations Corporation: Bluegreen Vacations Corporation (NYSE:BXG) is a leading vacation ownership company that markets and sells vacation ownership interests (VOIs) and manages resorts in top leisure and urban destinations. The Bluegreen Vacation Club is a flexible, points-based, deeded vacation ownership plan with approximately 216,000 owners, 69 Club and Club Associate Resorts and access to more than 11,000 other hotels and resorts through partnerships and exchange networks as of December 31, 2018. Bluegreen Vacations also offers a portfolio of comprehensive, fee-based resort management, financial, and sales and marketing services, to or on behalf of third parties. Bluegreen is approximately 90% owned by BBX Capital Corporation (BBX) (BBXTB), a diversified holding company. For further information, visit www.BluegreenVacations.com.
(1) See Note 2: Summary of Significant Accounting Policies within the December 31, 2018 annual report on Form 10-K for further discussion regarding the implementation of a new revenue recognition accounting standard.


Brochure – 45 minutes I changed the photograph on the inside to bleed on the left edge as well as the wave image above that photo. I worked a lot with typography on the inside story. I shortened it and made adjustments so that it would not overlap the fold. I also added color names to the color scheme list.
Web page – 15 minutes I changed the width of the page and changed the alignment of the footer to align with the web page title.
Event Ad – 20 minutes I took off the reflection of the title text and listed the beneficiary of the fund raiser.
I hope that this reflects my hard work and perseverance as I strive for excellence to display my work in a professional manner.
Since I am a teacher already, my main focus was to increase my knowledge and skills and learn things that I can pass on to my students.
None of my images came from the internet.
Description: This is a brochure promoting fun activities on Catalina Island by sharing a little of my experience, specifically riding Segways and parasailing.
Process (Programs, Tools, Skills): I decided to create a brochure promoting fun activities on Catalina Island. I had just been there with my sister and I had some great photos to work with. It would be a brochure that I would really enjoy working on. With that message in mind, I opened up Illustrator and began working on the logo. I created waves and a sun, two prominent elements of our fun day. Then I began designing the brochure in InDesign. I initially used a picture showing a larger sail on the front panel, but the sail was too large for moving it out and sizing larger for the bleed; it would have cut off the top and side of the sail (maybe that would have been okay?) I like the picture that I have now though because it shows the white wake of the water which curves around and down to the brochure title, "Catalina Fun" which creates a nice flow. On the inside of my brochure, I originally had the text on the left side, but it was right next to the Segway panel of text and the tutor pointed out that it was too much text all together, so I redesigned the inside and flipped the image horizontally and put it on the left. I created a "white wave" to separate the picture and the text block which I put on the right side. I decided to edit one of the photos in Photoshop and remove the background so that I could use the sail portion and wrap text around it. I originally put it in the top-middle of the parasailing text block. Most of my critiquers did not like it. During the re-design, I decided to put it in the upper right corner of my parasiling text block, so text only wraps around the left side of it. I think that looks better. I played with my alignment and typography a lot. The tutor told me that my bullets should be aligned with the picture and the heading (I thought that bullets were usually indented?) He also told me that I should align the brochure title/wave combination more to the left so that it was not centered, creating better flow with the wake of the water. It was challenging getting the text to look good in the parasailing text block. I decided to use full alignment so it would look nicely on the right hand side, as well as flow along the wave shape on the left. I normally don't like full alignment, but I really worked this one and hopefully, it is acceptable. This was more challenging than I thought it would be.
Sources (Links to images on original websites): these are photos taken by the crew member on the boat from Island Water Charters (www.islandwatercharters.com/parasailing.htm) (my sister bought the photo package and so we have the SD card) The picture of my sister and I on the segways was taken by the guy that took us on our segway tour, using my iPhone, so I got that picture from my phone.


text:
A big screen adaptation that serves as the continuation of the HBO TV series of the same name. Movie star Vincent Chase together with his boys, Eric, Turtle and Johnny, are back...and back in business with super agent-turned-studio head Ari Gold (Jeremy Piven). Some of their ambitions have changed, but the bond between them remains strong as they navigate the capricious and often cutthroat world of Hollywood.
Subtitle: Chinese
Classification: R21
Release Date: 4 Jun 2015
Cast: Adrian Grenier, Jeremy Piven, Mark Wahlberg, Emily Ratajkowski
Director: Doug Ellin
Writer: Cinnamon Lion
Watch this if you liked: "Get Shorty" and "The Producers"
The Good, The Bad and the Entourage:
•	The film feels like another HBO episode but on a bigger budget with a bigger screen and more famous cameos to boot.
•	Expectedly, the plot of the movie just skims through the surface to maintain its 'entertaining' style and any hopes of a more profound plot quickly transitions away once things start getting too deep.
•	While the rest of the cast sometimes border on being too dull and predictable, the real winner here is Jeremy Piven's Ari Gold who delivers some of the best scenes and laughs!
Cinema Online, 08 June 2015

redpajama_set_name: RedPajamaCommonCrawl


I was on my side porch the other day, chilling, enjoying the breeze, and doing a bit of writing for work, when I looked through the trees over to my neighbor's yard and saw a huge pink flamingo.
Now I probably should clarify that through the trees was their pool. And that the pink flamingo was a float – the largest one I'd ever seen (and all I saw was the long neck, large head, and yellow and black beak).
So what does that, in any way, have to do with leadership?
Well, perhaps needless to say, the pink flamingo head popping up through the trees made me smile. Which made me realize that I probably hadn't smiled for quite some time today. Which made me think of all the time I spend head down, focused on work (or life), not smiling, and of all the time my clients most likely do as well.
And, as we've written before, smiling, enjoying, and even laughing are essential leadership tools.
So, as summer is about to officially start, and the temperatures where I live begin to soar, I want to recognize that plastic pink flamingo float, and all other reminders of fun and instigators of giggling, guffawing, and smiling.
There are many essential leadership skills, and bringing a sense of lightness to the teams and organizations (and families) we lead is certainly one of them. There are many important leadership tools, and pink flamingo floats seem to be one of them as well.
Let's challenge ourselves to celebrate summer, fun, and levity – and to bring a sense of laughter and play to our work (and our play). Let's celebrate pink flamingo floats.
How do you bring a sense of fun and play to your team?
If you want more play – and pink flamingoes – contact Lisa at lkohn@chatsworthconsulting.com.
Great Deirdre. Enjoy it. It still makes me laugh every time I see it.


text:
Circular RNA SMARCA5 correlates with favorable clinical tumor features and prognosis, and increases chemotherapy sensitivity in intrahepatic cholangiocarcinoma
Lu Qi, Fang Tao
https://doi.org/10.21203/rs.2.17259/v1
posted 13 Nov, 2019
Background This present study aimed to investigate the correlation of circular RNA SMARCA5 (circ-SMARCA5) with clinicopathological features and overall survival (OS), and the effect of circ-SMARCA5 on cell proliferation and chemotherapy sensitivity to cisplatin/gemcitabine in intrahepatic cholangiocarcinoma (ICC).
Methods Totally 92 primary ICC patients who underwent resection were recruited, and their tumor tissues, adjacent tissues were collected for circ-SMARCA5 detection. The effect of circ-SMARCA5 on cell proliferation and chemotherapy sensitivity was detected after circ-SMARCA5 overexpression plasmids transfection into TFK-1 and HuH-28 ICC cells.
Results Circ-SMARCA5 expression was reduced in ICC tumor tissues compared to adjacent tissues. Tumor circ-SMARCA5 high expression was negatively associated with Eastern Cooperative Oncology Group performance score, T stage, N stage, TNM stage and abnormal CA199 status. Furthermore, OS was increased in patients with tumor circ-SMARCA5 high expression compared with those with low expression, and further multivariate Cox's regression demonstrated that tumor circ-SMARCA5 high expression was an independent predictive factor for longer OS. In TFK-1 and HuH-28 ICC cells, circ-SMARCA5 upregulation decreased cell proliferation, reduced relative cell viability in cisplatin-treated as well as gemcitabine-treated cells, and also decreased inhibitory concentration by 50% value (IC50) of cisplatin and gemcitabine.
Conclusions The correlation of circ-SMARCA5 with favorable clinical tumor features, survival profile, and its promoting effect on chemotherapy sensitivity imply its potential as a valuable biomarker in monitoring disease progression and prognosis of ICC.
Circular RNA SMARCA5
Cell proliferation
Chemotherapy sensitivity
Intrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC), as the second most common primary liver cancer, is a hepatobiliary malignancy located proximally to the second degree bile ducts, and its incidence is increasing in the last twenty years [1, 2]. Surgical resection is considered to be the only potentially curative treatment with 5-year survival rates ranging from 30%–40%, and remains as the cornerstone of therapy for ICC patients [3]. Besides, other treatments consist of neoadjuvant/adjuvant therapy, intensive cytotoxic therapy, hepatic arterial infusion therapy, embolization therapy and etc., which help improve clinical outcomes in the ICC patients [4–7]. However, there are still a large number of ICC patients suffering from poor long-term survival due to a high risk of recurrence, node metastasis, vascular invasion and increasing chemotherapy resistance [3, 5]. Therefore, research focusing on the discovery of novel biomarkers is essential, which can be used in the clinical application and improve the long-term therapeutic efficacy.
Circular RNAs (circRNAs) represent a large amount of noncoding RNA transcripts, whose biology functions in cellular differentiation, physiological homeostasis and even tumorigenesis are revealed by accumulating publications in the last decade [8]. CircRNA SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5 (circ-SMARCA5) is a circRNA derived from exons 15 and 16 of SMARCA5 gene, and SMARCA5 gene has effect on regulating activities of helicase and ATPase, remodeling chromatin, facilitating the transcription of class II genes [9]. Previous published papers indicate that circ-SMARCA5 is downregulated and exerts anti-tumor effects in various cancers, such as hepatocellular carcinoma (HCC), non-small cell lung cancer, gastric cancer and cervical cancer [10–13]. For example, in HCC, circ-SMARCA5 is downregulated in HCC tissues, and its downregulation is associated with aggressive tumor features as well as unfavorable survival profiles in HCC patients [12, 14]. And in vivo experiments reveals that circ-SMARCA5 inhibits HCC cell proliferation and migration [14]. Considering that ICC and HCC share some similarities in molecular profiles, dominant risk factors and clinical manifestations, therefore, we speculated that circ-SMARCA5 might be involved in the ICC development and progression [15, 16]. In the current study, we aimed to investigate the correlation of circ-SMARCA5 expression with clinical characteristics and survival profiles in ICC patients, and further conducted the cellular experiments to discover the role of circ-SMARCA5 in regulating cell proliferation and drug sensitivity of ICC.
This prospective study consecutively enrolled 92 primary ICC patients who underwent resection in our hospital between July 2014 and June 2016. The inclusion criteria were (i) newly diagnosed as primary ICC by imageology and histopathology; (ii) 18 years≤age≤80 years; (iii) clinical condition was suitable for surgery and about to receive resection; (iv) without other malignancies. The excluded criteria were: (i) HCC or mixed HCC-ICC; (ii) received neoadjuvant therapy before enrollment; (iii) with distant metastasis; (iv) history of human immunodeficiency virus infection; (v) pregnant or lactating women. This study was approved by Ethics Committee of our hospital and was conducted according to the principles expressed in the Declaration of Helsinki. All patients or their guardians provided the written informed consents.
Data and sample collection
The clinical characteristics of patients were recorded after enrollment, which included age, gender, smoke, drink, hepatitis B virus (HBV) infection, Eastern Cooperative Oncology Group (ECOG) performance score, pathological differentiation, T stage, N stage, TNM stage, carcinoembryonic antigen (CEA) level and carbohydrate antigen 199 (CA199) level. Tumor tissue and paired adjacent tissue resected from surgery were stored in liquid nitrogen, immediately. And the tumor tissue and adjacent tissue were divided into two parts, one was used for pathological diagnosis, another was used for circ-SMARCA5 detection in this study.
The relative expression of circ-SMARCA5 in tumor tissue and adjacent tissue was detected by RT-qPCR. Total RNA was firstly extracted from tumor tissues and adjacent tissues using TRIzol Reagent (Invitrogen, USA), and linear RNA was removed using RNase R (Epicentre, USA). Following that, RNA was reversely transcribed to cDNA using iScript™ cDNA Synthesis Kit (Bio-Rad, USA). Finally, qPCR was conducted using THUNDERBIRD® SYBR® qPCR Mix (Toyobo, Japan). All the procedures were carried out according to the protocols of manufacturers. Then circ-SMARCA5 expression was calculated using 2-△△Ct with GAPDH as internal reference. The primer sequences used for RT-qPCR were listed as followed: Circ-SMARCA5 forward: ACAATGGATACAGAGTCAAG, reverse: CTTCATCAGTGATCTCACT; GAPDH forward: TGACCACAGTCCATGCCATCAC, reverse: GCCTGCTTCACCACCTTCTTGA.
According to the relative expression of circ-SMARCA5 in tumor tissue, all patients were classified as circ-SMARCA5 high expression group (50%-100% quantile of circ-SMARCA5 relative expression in tumor tissue, n=46) and circ-SMARCA5 low expression group (0%-50% quantile of circ-SMARCA5 relative expression in tumor tissue, n=46). In addition, the circ-SMARCA5 low expression group was further divided into circ-SMARCA5 low- expression group (25%-50% quantile of circ-SMARCA5 relative expression in tumor tissue, n=23), circ-SMARCA5 low-- expression group (10%-25% quantile of circ-SMARCA5 relative expression in tumor tissue, n=14) and circ-SMARCA5 low--- expression group (0%-10% quantile of circ-SMARCA5 relative expression in tumor tissue, n=9).
Treatment and follow-up
After resection, all patients received gemcitabine/cisplatin combination adjuvant treatment based on the status of margins, according to NCCN Guidelines for Intrahepatic Cholangiocarcinoma [17]. Continuous follow-up was carried out for the patients until 2019/06/30. The median duration of follow-up was 26.5 months ranging from 2.0 to 60.0 months. Overall survival (OS) was defined as the duration from enrollment to death, and for the patients not known to have died in the last follow-up date, they were censored on the date of last known to be alive. Because most patients in the current study were non-local patients and the precise disease status of them was unbale to acquire timely, consequently, the disease-free survival (DFS) was not evaluated.
Human ICC cell line TFK-1 was purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen (Braunschweig, German), while another human ICC cell line HuH-28 was purchased from Japanese Cancer Research Resources Bank - Cell Bank (Tokyo, Japan). TFK-1 cells were cultured in 90% Roswell Park Memorial Institute (RPMI) 1640 Medium (Gibco, USA) and 10% fetal bovine serum (FBS) (Gibco, USA) under 95% air 5% CO2 at 37 ℃, while HuH-28 cells were cultured in 80% RPMI 1640 Medium (Gibco, USA) and 20% FBS (Gibco, USA) under 95% air 5% CO2 at 37 ℃.
The pCD5-ciR vector (Geneseed Biotech Co., Ltd, China) was used to structure circ-SMARCA5 over-expression (OE) plasmid and control OE plasmid. After construction, the OE plasmids were transfected into HuH-28 cells and TFK-1 cells using Lipofectamine 2000 (Thermo, USA), then the cells transfected with circ-SMARCA5 OE plasmids were marked as OE-Circ group, correspondingly, the cells transfected with control OE plasmids were termed as OE-Control group. After transfection, cell proliferation in both groups were measured at 0h, 24h, 48h and 72h using Cell Counting Kit-8 (Sigma, USA), and the procedure was in accordance with manufacturer's manual.
Drug sensitivity
At 24h after transfection, the OE-Circ cells and OE-Control cells were plated in 96 multi-well plates with a concentration of 5000 cells/well. Then the cells were treated with several concentrations of Cisplatin (Sigma, USA) and Gemcitabine (Sigma, USA) for 72h, respectively. After 72h treatment, the cell viability of the OE-Circ cells and OE-Control cells at different drug concentrations was determined by Cell Counting Kit-8 (Sigma, USA), and the procedure was in accordance with manufacturer's manual. The cells treated with 0 μM Cisplatin or 0 μM Gemcitabine in each group were used as the reference in calculation of relative cell viability. Further, the drug concentration required to inhibit growth by 50% (IC50) was calculated for all treated cells with the use of Probit regression analysis.
Continuous variables were displayed as mean±standard deviation (SD) or median and interquartile range (IQR), and the categorical variables were expressed as count and percentage. Comparisons of unpaired variable between two groups were determined by Student's t test or Chi-square test. Comparisons of paired variable between two groups were determined by Wilcoxon signed rank test. OS was illustrated using Kaplan–Meier curve, and the difference of OS between/among groups was determined by Log-rank test. Factors predicting OS were analyzed by univariate Cox's proportional hazard regression model and forward stepwise multivariate Cox's regression model. All statistical analyses were performed using SPSS 22.0 software (IBM, USA), and figures were made using GraphPad Prism 7.00 software (GraphPad Software, USA). All tests were two-sided, P value<0.05 was considered as significant.
Clinical characteristics of ICC patients
In total ICC patients, the mean age was 59.2±7.4 years, and there were 27 (29.3%) females and 65 (70.7%) males (Table 1). Regarding ECOG performance score, there were 57 (62.0%) patients with 0, and 35 (38.0%) patients with 1/2. As for pathological differentiation, there were 55 (59.8%) patients with well/moderate pathological differentiation, and 37 (40.2%) patients with poor pathological differentiation. The number of patients with I/II and III/IV TNM stage were 54 (58.7%) and 38 (41.3%) respectively. More detailed clinical characteristics were shown in Table 1.
Comparison of Circ-SMAECA5 in ICC tumor tissues and pair adjacent tissues
Circ-SMARCA5 relative expression was reduced in ICC tumor tissues (0.311 (0.179-0.602)) compared with adjacent tissues (0.987 (0.709-1.297) (P <0.001) (Figure 1).
Correlation of circ-SMAECA5 expression with clinical features in ICC patients
All ICC patients were divided into circ-SMARCA5 high expression group (n=46) and circ-SMARCA5 low expression group (n=46) according to 50% quantile of circ-SMARCA5 relative expression in tumor tissue. Circ-SMARCA5 expression was negatively associated with ECOG performance score (P <0.001), T stage (P <0.036), N stage (P <0.001), TNM stage (P <0.001) and abnormal CA199 status (P =0.019), however, there was no association of circ-SMARCA5 expression with age (P =0.372), gender (P =0.819), smoke (P =0.381), drink (P =0.294), HBV infection (P =0.393), pathological differentiation (P =0.524) or CEA (P =0.524) in ICC patients (Table 1).
Correlation of circ-SMARCA5 expression with OS in ICC patients
OS was increased in patients with circ-SMARCA5 high expression compared with those with circ-SMARCA5 low expression (P =0.007) (Figure 2A). Furthermore, circ-SMARCA5 low expression group was divided into circ-SMARCA5 low- expression group (25%-50% quantile of circ-SMARCA5 relative expression in tumor tissue), circ-SMARCA5 low-- expression group (10%-25% quantile of circ-SMARCA5 relative expression in tumor tissue) and circ-SMARCA5 low--- expression group (0%-10% quantile of circ-SMARCA5 relative expression in tumor tissue). OS was the highest in patients with circ-SMARCA5 high expression, followed by patients with circ-SMARCA5 low- expression and patients with circ-SMARCA5 low-- expression, and then patients with circ-SMARCA5 low--- expression (P <0.001) (Figure 2B).
Factors affecting OS in ICC patients
Univariate Cox's regression analysis exhibited that circ-SMARCA5 high expression (HR=0.535, P =0.008) was associated with longer OS, while higher ECOG performance score (HR=2.060, P =0.003), poor pathological differentiation (HR=2.896, P <0.001), advanced TNM stage (HR=2.371, P <0.001) were correlated with reduced OS in ICC patients (Table 2). And forward stepwise multivariate Cox's regression analysis presented that circ-SMARCA5 high expression was an independent predictive factor for increased OS (HR=0.518, P =0.006), poor pathological differentiation was an independent predictive factor for decreased OS (HR=2.979, P <0.001) in ICC patients.
Effect of circ-SMARCA5 upregulation on cell proliferation in ICC cells
We conducted the in vitro experiments to explore the effect of circ-SMARCA5 upregulation on cell proliferation in two ICC cell lines. In HuH-28 ICC cells, cell proliferation was reduced in OE-Circ group compared with OE-Control group at 48h (P <0.05) and 72h (P <0.01) after transfection (Figure 3A). As for in TFK-1 cells, cell proliferation was also decreased in OE-Circ group compared with OE-Control group at 48h (P <0.05) and 72h (P <0.05) after transfection (Figure 3B).
Effect of circ-SMARCA5 upregulation on chemotherapy sensitivity to cisplatin/gemcitabine in ICC cells
Further experiments were performed to investigate the effect of circ-SMARCA5 upregulation on chemotherapy sensitivity to cisplatin/gemcitabine in two ICC cell lines. In HuH-28 cells, relative cell viability was decreased in OE-Circ group compared with OE-Control group in 4μM (P <0.05), 8μM (P <0.05), 16μM (P <0.05) cisplatin-treated cells (Figure 4A); relative cell viability was also reduced in OE-Circ group compared with OE-Control group in 4μM (P <0.01), 8μM (P <0.01), 16μM (P <0.05) gemcitabine-treated cells (Figure 4B). Furthermore, IC50 value of cisplatin (P <0.01) (Figure 4C) and gemcitabine (P <0.001) (Figure 4D) were both decreased in OE-Circ group compared with OE-Control group. Similarly, in TFK-1 cells, relative cell viability was reduced in OE-Circ group compared with OE-Control group in 16μM (P <0.05), 32μM (P <0.05) and 64μM (P <0.05) cisplatin-treated cells (Figure 4E); relative cell viability was also decreased in OE-Circ group compared with OE-Control group in 8μM (P <0.05), 16μM (P <0.05) gemcitabine-treated cells (Figure 4F). IC50 value of cisplatin (P <0.01) (Figure 4G) and gemcitabine (P <0.01) (Figure 4H) were both decreased in OE-Circ compared with OE-Control. These suggested that circ-SMARCA5 upregulation promoted chemotherapy sensitivity to cisplatin/gemcitabine in ICC cells.
In the current study, we found that (1) circ-SMARCA5 was downregulated in ICC tumor tissues compared with adjacent tissues; (2) circ-SMARCA5 was negatively associated with ECOG performance score, TNM stage and abnormal CA199 status in ICC patients. (3) circ-SMARCA5 was an independent predictive factor for increased OS in ICC patients. (4) circ-SMARCA5 upregulation inhibited cell proliferation, and increased cell chemotherapy sensitivity to cisplatin/gemcitabine in ICC.
CircRNAs have been identified to be expressed stably in various cells, and they are reported to be involved in various physiological development, including serving as microRNA sponges, interacting with proteins, regulating transcription and splicing, participating in translation and etc. [8, 18, 19]. Until now, there are only preliminary investigations focusing on the role of circRNAs in cancers [19]. However, regarding circ-SMARCA5, as one of circRNAs, several publications reveal its participation in the tumorigenesis of various tumors, and circ-SMARCA5 high expression is reported to be correlated with favorable clinicopathological features and prognosis in patients with cancers [10, 11, 13, 20]. For example, circ-SMARCS5 is greatly downregulated in gastric cancer tissues compared with adjacent noncancerous tissues, and correlates with well differentiation, negative lymph node metastasis, no vascular invasion, and favorable prognosis in patients with gastric cancer [13]. In addition, circ-SMARCA5 is found to be downregulated in glioblastoma multiforme biopsies compared to normal brain tissues, and there exists a negative correlation between circ-SMARCA5 expression and histological grade in patients with glioma [20]. Furthermore, circ-SMARCA5 expression is decreased in HCC tissues compared with adjacent tissues, and its downregulation is correlated with advanced tumor features, furthermore, circ-SMARCA5 serves as an independent predictive factor for longer recurrence-free survival and OS in patients with HCC after hepatectomy [12]. However, the research on the role of circ-SMARCA5 in ICC has not conducted yet. Considering the similarities of cellular origin, genomic mutations, risk factors between ICC and HCC, we speculated that circ-SMARCA5 might also be aberrantly expressed in ICC tissues, and correlated with tumor features in ICC patients [15, 16]. We found that circ-SMARCA5 was downregulated in ICC tumor tissues compared with adjacent tissues, and was negatively associated with ECOG performance score, TNM stage and abnormal CA199 status in ICC patients. The possible reasons might include that: Circ-SMARCA5 might inhibit cell proliferation, migration and invasion via acting as the miRNA sponge (such as: miR–17–3p and miR–181b–5p, which served as targets of circ-SMARCA5 in HCC) in ICC, which contributed to the tumor-inhibitory effect on ICC progression, therefore, circ-SMARCA5 is correlated with favorable clinicopathological features in ICC patients; however, this speculation needed to be further verified by cellular experiments in ICC [10]. In addition, as for the correlation of circ-SMARCA5 with survival profile in ICC patients, we observed that circ-SMARCA5 was an independent predictive factor for increased OS in ICC patients. This might be explained by that (1) circ-SMARCA5 was negatively associated with ECOG performance score, TNM stage and abnormal CA199 status in ICC patients, which were known as predictive factor for ICC prognosis. Therefore, circ-SMARCA5 might lead to desirable prognosis via interaction with these clinical-pathological tumor features. (2) Circ-SMARCA5 might be associated with SMARCA5-related functions (including: DNA repair and protection against the adverse effects of DNA damage) via activating DNA damage response, contributing to improved drug sensitivity, which was validated in our further functional experiments that circ-SMARCA5 increased cell chemotherapy sensitivity to cisplatin and gemcitabine in ICC. Thus, patients with circ-SMARCA5 high expression had increased survival in a long-term period compared with those with circ-SMARCA5 low expression [21].
Existing evidence demonstrates that circ-SMARCA5 are not simply by-products of gene splicing, but are of functionality and involved in regulating cell activities in various cancers [10, 11, 14, 20]. For example, in cervical cancer, upregulation of circ-SMARCA5 inhibits cell proliferation, migration and invasion, and caused cell cycle arrest via being miR–620 sponge, suggesting the anti-tumor properties of circ-SMARCA5 [11]. In addition, circ-SMARCA5 promotes the expression of an anti-tumor gene, TIMP3, via functioning as the sponge of miR–181b and miR–17, resulting in inhibitory effect on HCC cell proliferation and migration [14]. However, the regulatory function of circ-SMARCA5 on cell activities in ICC has not been investigated yet. We found that upregulation of circ-SMARCA5 suppressed ICC cell proliferation, improved cell chemotherapy sensitivity to cisplatin as well as gemcitabine. The possible reasons might include that (1) Upregulation of circ-SMARCA5 might activate the expressions of anti-tumor genes (such as: TIMP3), which inhibited cell proliferation in ICC. (2) According to the previous study, cisplatin and gemcitabine are accepted as the standard chemotherapy regimen for ICC, and their abilities include involvement in DNA repair mechanisms, inducing cancer cell apoptosis, inhibitory effect in DNA damage [2, 22]. Furthermore, circ-SMARCA5 might boost the DNA-repair ability and acquire resistance to DNA damaging agents via its located gene (SMARCA5), which reduced the formation of the drug resistance [21]. Thus circ-SMARCA5 upregulation might enhance the drug sensitivity (cisplatin and gemcitabine) in ICC cells. Combining the findings of cellular experiments and clinical research in our study, circ-SMARCA5 is suggested to be a candidate prognostic biomarker in ICC.
In conclusion, circ-SMARCA5 is downregulated in tumor tissues and correlates with favorable clinicopathological features and survival profile in ICC patients, and its upregulation not only inhibits proliferation, but also increases chemotherapy sensitivity to cisplatin and gemcitabine in ICC cells.
ICC, Intrahepatic cholangiocarcinoma; circ-SMARCA5, CircRNA SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen; CA199, carbohydrate antigen 199; RT-qPCR, Reverse transcription quantitative polymerase chain reaction; OS, Overall survival; DFS, disease-free survival; RPMI, Roswell Park Memorial Institute; FBS, fetal bovine serum; OE, over-expression; IC50, the drug concentration required to inhibit growth by 50%; SD, standard deviation; IQR, interquartile range.
This study was approved by Ethics Committee of our hospital and was conducted according to the principles expressed in the Declaration of Helsinki. All patients or their guardians provided the written informed consents.
Availability of data and material
All data generated or analysed during this study are included in this published article.
LQ and FT designed and coordinated the study, made substantial contributions to the analysis, and drafted the manuscript. LQ performed statistical analysis. LQ and FT participated in data collection and interpretation. LQ helped to draft the manuscript. FT reviewed the manuscript and exerted a major impact on the interpretation of data and critical appraisal of the manuscript. All authors have read and approved the final manuscript.
1.Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014; 383:2168–79.
2.Chun YS, Javle M. Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma. Cancer Control. 2017; 24:1073274817729241.
3.Ahn DH, Javle M, Ahn CW, Jain A, Mikhail S, Noonan AM et al. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer. 2016; 122:3657–66.
4.Ribero D, Pinna AD, Guglielmi A, Ponti A, Nuzzo G, Giulini SM et al. Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 434 Patients. Arch Surg. 2012; 147:1107–13.
5.Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist. 2008; 13:415–23.
6.Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol. 2010; 28:3531–40.
7.Weber SM, Ribero D, O'Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015; 17:669–80.
8.Kristensen LS, Hansen TB, Veno MT, Kjems J. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene. 2018; 37:555–65.
9.LeRoy G, Orphanides G, Lane WS, Reinberg D. Requirement of RSF and FACT for transcription of chromatin templates in vitro. Science. 1998; 282:1900–4.
10.Wang Y, Li H, Lu H, Qin Y. Circular RNA SMARCA5 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by miR–19b–3p/HOXA9 axis. Onco Targets Ther. 2019; 12:7055–65.
11.Tian JDC, Liang L. Involvement of circular RNA SMARCA5/microRNA–620 axis in the regulation of cervical cancer cell proliferation, invasion and migration. Eur Rev Med Pharmacol Sci. 2018; 22:8589–98.
12.Yu J, Xu QG, Wang ZG, Yang Y, Zhang L, Ma JZ et al. Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma. J Hepatol. 2018; 68:1214–27.
13.Cai J, Chen Z, Zuo X. circSMARCA5 Functions as a Diagnostic and Prognostic Biomarker for Gastric Cancer. Dis Markers. 2019; 2019:2473652.
14.Li Z, Zhou Y, Yang G, He S, Qiu X, Zhang L et al. Using circular RNA SMARCA5 as a potential novel biomarker for hepatocellular carcinoma. Clin Chim Acta. 2019; 492:37–44.
15.Lendvai G, Szekerczes T, Illyes I, Dora R, Kontsek E, Gogl A et al. Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis. Pathol Oncol Res. 2018.
16.Wang M, Gao Y, Feng H, Warner E, An M, Jia J et al. A nomogram incorporating six easily obtained parameters to discriminate intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Cancer Med. 2018; 7:646–54.
17.NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers (Version 2.2014).
18.Xu Y, Yao Y, Liu Y, Wang Z, Hu Z, Su Z et al. Elevation of circular RNA circ_0005230 facilitates cell growth and metastasis via sponging miR–1238 and miR–1299 in cholangiocarcinoma. Aging (Albany NY). 2019; 11:1907–17.
19.Merdrignac A, Angenard G, Allain C, Petitjean K, Bergeat D, Bellaud P et al. A novel transforming growth factor beta-induced long noncoding RNA promotes an inflammatory microenvironment in human intrahepatic cholangiocarcinoma. Hepatol Commun. 2018; 2:254–69.
20.Barbagallo D, Caponnetto A, Cirnigliaro M, Brex D, Barbagallo C, D'Angeli F et al. CircSMARCA5 Inhibits Migration of Glioblastoma Multiforme Cells by Regulating a Molecular Axis Involving Splicing Factors SRSF1/SRSF3/PTB. Int J Mol Sci. 2018; 19.
21.Aydin OZ, Vermeulen W, Lans H. ISWI chromatin remodeling complexes in the DNA damage response. Cell Cycle. 2014; 13:3016–25.
22.Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014; 740:364–78.
Table 1. Clinical characteristics
Total patients (N=92)
Circ-SMARCA5
Low (n=46)
High (n=46)
Age (years), mean±SD
Gender, No. (%)
Smoke, No. (%)
Drink, No. (%)
HBV infection, No. (%)
ECOG performance score, No. (%)
Pathological differentiation, No. (%)
Well and moderate
T stage, No. (%)
T1/T2
N stage, No. (%)
TNM stage, No. (%)
I/II
III/IV
CEA abnormal*, No. (%)
CA199 abnormal#, No. (%)
Comparison was determined by Student's t test or Chi-square test. ICC, intrahepatic cholangiocarcinoma; SD, standard deviation; HPV, hepatitis B virus; ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen; CA199, carbohydrate antigen 199. *abnormal, CEA>5 ng/mL; normal, CEA≤5 ng/mL; #abnormal, CA199>37 U/mL; normal, CA199≤37 U/mL.
Table 2. Analysis of factors predicting OS
Cox's proportional hazard regression model
95%CI
Univariate Cox's regression
Low expression
High expression
≤60 years
HBV infection
ECOG performance score
Pathological differentiation
Well/moderate
TNM stage
CEA *
CA199 #
Forward stepwise multivariate Cox's regression
Pathological differentiation (poor)
Factors predicting OS were analyzed by univariate Cox's proportional hazard regression model and forward stepwise multivariate Cox's regression model. OS, overall survival; HR, hazard ratio; CI, confidence interval; HPV, hepatitis B virus; ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen; CA199, carbohydrate antigen 199. CEA>5 ng/mL; normal, CEA≤5 ng/mL; #abnormal, CA199>37 U/mL; normal, CA199≤37 U/mL.


text:
Celebrate World Turtle Day
We'll help shine a light on the oldest living reptiles in the world
It's World Turtle Day, an annual event on May 23 that was started by the American Tortoise Rescue with the goal of putting a spotlight on the care, conservation and awareness of these amazing creatures.
Not only do they come in various shapes and sizes, but they are the oldest living reptiles in existence, having roamed the Earth for between 200 to 300 million years.
It's estimated that there are approximately 300 different species in existence today, spending their time on land, in freshwater and in the ocean.
Some, such as Blanding's turtles, are on Illinois' state endangered list. Currently, the District is part of the regional Blanding's Turtle Recovery Program to help save them.
If you've ever set foot in one of the District's preserves, odds are you've seen a turtle or two, whether it was in the water, catching some sun on a log or slowly crossing a path.
Here's a glance at a number of species that can be found out in the wild in Will County.
Red-eared Slider
There's no mystery how this turtle gets its name. The first telltale sign is the red patch on both sides of its head, as well as being known to slide into the water whenever there is the slightest hint of danger.
Their range includes the Midwest, and they often have been kept as pets. Unfortunately, they also have many times been released into the wild when their owners no longer wanted them.
They are adaptable to many climates, and can most often be found near water, either swimming in it or basking in the sun on rocks or logs. Water serves as a place to hide for this turtle when predators approach.
Northern Map Turtle
(Photo courtesy of Joel Craig)
Much like the red-eared slider, the northern map turtle gets its name based on its visual appearance, thanks to its shell that has markings looking similar to a topgraphical map.
They can generally be found in rivers and lakes with slow moving water, and have a tendency to gather in spots with a number of different areas to bask in the sun.
Females will lay their eggs in June and July — up to 17 at eggs once — and they will hatch in the fall.
Not sure how to tell the difference between a female and a male? The females will be larger, ranging from seven to 11 inches long, while the males measure between three and six inches.
Painted Turtle
It's the most widespread native turtle in North America, and can be found living in ponds, lakes, marshes and rivers that have slow-moving water.
Much like the red-eared slider, they'll hit the water at the first sign of danger to avoid predators, which can include raccoons, otters, foxes and any other medium-sized critters looking for a meal courtesy of the turtle or its eggs.
Their vibrant color makes them easy to spot and a stunning specimen to photograph.
Snapping Turtle
(Photo courtesy of Kevin Keyes)
These beasts can be quite a sight, with nearly all adults weighing in excess of 20 pounds. They continue to grow throughout their lifetime, with the largest snapping turtle caught in captivity reportedly weighing 75 pounds.
They also can be quite combative, with the potential to use their beak-like jaw to deliver quite a painful bite if given the opportunity.
They prefer waters with muddy bottoms and plentiful vegetation to provide some protective cover. They'll often bury themselves, only leaving their eyes and nostrils exposed.
Whether it's fish, birds, insects or other small mammals, they'll chow down whatever is available.
Every now and then, trail users are lucky enough to spot them in some serious mating activity along Centennial Trail.
Spotted Turtle
(Photo via Shutterstock)
Spotted turtles get their name from, you guessed it, the promintent yellow spots on their smooth and dark shells.
Occasionally, spotted turtles will lack those distictive markings, but can still be identified by orange and yellow markings on their face.
They can be found in Illinois, as well as along the Eastern Seaboard and portions of the South.
Their activity heats up in the spring after hibernating all winter, then slows down during the hottest parts of the summer when they'll burrow themselves into water. Not only does this keep them cool, but it helps them hide from raccoons, one of their main predators on land.
Three-toed Box Turtle
(Photo by Chad Merda)
Three-toed box turtles aren't native to Illinois, but one is living at Plum Creek Nature Center after being taken in as a rescue.
Smash was found wandering outdoors and staff decided to give him a forever home.
"Since they are not from here, they cannot survive our winter and they could introduce bacteria into the environment that could hurt native turtles," interpretive naturalist Bob Bryerton said.
The turtles' home turf is Missouri, Tennessee and other southern states.
The Plum Creek Nature Center resident is believed to be in his mid-20s and there's a good chance he'll hit the century mark.
"Smash is a huge hit with visitors," Bryerton said. "Kids come in and love to see if they can find him in his cage. He is so gentle and shy and moves so slowly the kids just love him."
Softshell Turtle
Softshell turtles definitely are unique, with their shells being smooth and leathery and lacking any plates. They also are flatter than their turtle counterparts, with more of a pancake-like appearance.
Females can be twice as large as the males (14 inches long compared to seven inches), and they'll mate from April until May.
Much like the snapping turtle, it will bury itself, only allowing its head to stick out of water to breathe.


text:
Diocese of Leopoldina
Dioecesis Leopoldinensis
Edson José Oriolo dos Santos, Bishop
Type of Jurisdiction: Diocese
Erected: 28 March 1942
Metropolitan: Archdiocese of Juiz de Fora
Rite: Latin (or Roman)
State: Minas Gerais
Square Kilometers: 8,491 (3,279 Square Miles)
Conference Region: Leste 2
Official Web Site: http://dioceseleopoldina.com/
Mailing Address: Curia Diocesana, C.P. 7, Praca Dom Helvecio 75, 36700-000 Leopoldina, MG, Brazil
Telephone: (032)3441-2008
Fax: (same)
Delfim Ribeiro Guedes † (26 Jun 1943 Appointed - 23 Jul 1960 Appointed, Bishop of São João del Rei, Minas Gerais)
Geraldo Ferreira Reis † (16 Jun 1961 Appointed - 5 Aug 1985 Retired)
Sebastião Roque Rabelo Mendes † (5 Aug 1985 Appointed - 10 May 1989 Resigned)
Ricardo Pedro Chaves Pinto Filho, O. Praem. † (14 Mar 1990 Appointed - 16 Oct 1996 Appointed, Archbishop of Pouso Alegre, Minas Gerais)
Célio de Oliveira Goulart, O.F.M. † (24 Jun 1998 Appointed - 9 Jul 2003 Appointed, Bishop of Cachoeiro do Itapemirim, Espirito Santo)
Dario Campos, O.F.M. (23 Jun 2004 Appointed - 27 Apr 2011 Appointed, Bishop of Cachoeiro do Itapemirim, Espirito Santo)
José Eudes Campos do Nascimento (27 Jun 2012 Appointed - 12 Dec 2018 Appointed, Bishop of São João del Rei, Minas Gerais)
Edson José Oriolo dos Santos (30 Oct 2019 Appointed - )
28 March 1942 Erected Archdiocese of Juiz de Fora
Archdiocese of Mariana Diocese of Leopoldina (erected)
1950 420,000 450,000 93.3% 34 8 42 10,000 8 165 34 ap1951
1966 400,000 415,000 96.4% 62 61 123 3,252 61 195 39 ap1967
1970 380,000 416,987 91.1% 34 24 58 6,551 25 155 41 ap1971
1999 396,865 529,154 75.0% 38 17 55 7,215 1 17 143 56 ap2000
2013 423,000 606,000 69.8% 52 10 62 6,822 10 61 61 ap2014
2016 423,390 601,000 70.4% 56 9 65 6,513 9 60 61 ap2017
Dario Campos, O.F.M. (Bishop: 23 Jun 2004 to 27 Apr 2011)
José Eudes Campos do Nascimento (Bishop: 27 Jun 2012 to 12 Dec 2018)
Otacilio Francisco Ferreira de Lacerda
Edson José Oriolo dos Santos (Bishop: 30 Oct 2019 - )
Walter Jorge Pinto
Ricardo Pedro Chaves Pinto Filho, O. Praem. † (Bishop: 14 Mar 1990 to 16 Oct 1996)
Célio de Oliveira Goulart, O.F.M. † (Bishop: 24 Jun 1998 to 9 Jul 2003)
Geraldo Ferreira Reis † (Bishop: 16 Jun 1961 to 5 Aug 1985)
Sebastião Roque Rabelo Mendes † (Bishop: 5 Aug 1985 to 10 May 1989)
Delfim Ribeiro Guedes † (Bishop: 26 Jun 1943 to 23 Jul 1960)
Code: web_d, v3.3.3, 8 Feb 2020; Data: 11 Mar 2020


Secure emails on the go mobile users while enhancing UX.
CA Mobile Email Management (CA MEM) offers comprehensive email security for your on-the-go mobile users in a bring your own device (BYOD) environment. CA MEM was designed to deliver end-to-end, data-centric security and mobile email encryption while maintaining a native email user experience.
Flexible on-premises and SaaS solution deployment options enable you to use CA MEM inside or outside your company's firewall. With automatic mobile email encryption, it can secure data with less staff intervention and give you more control of your company's data. Users can enjoy normal device usage and employee interaction—without compromising security.
CA MEM's mobile email encryption ensures the secure location of sensitive content. By preventing secure content from being pushed to cloud systems, CA MEM maintains secure content sent externally and internally. And in case of accidental or malicious exposure, CA MEM is capable of revoking access to email even after it has been received by the recipient.
Secure emails on all devices—mobile and non-mobile.
Prevent email access from unmanaged or non-compliant devices.
Protect confidential data within the mobile inbox with mobile email encryption.
Reduce the chance of brute force attack with multi-factor authentication.
Provide a great user experience with seamless secured email delivery.


text:
Image by Paul Biris / Getty Images
Europe/
Moldavia & the Bucovina Monasteries
Less visited than other parts of Romania, Moldavia rewards those intrepid enough to seek it out: from glorious medieval monasteries to rugged mountains ideal for hiking, this singular region combines natural beauty with plenty of action. Moldavia's bucolic villages and oddly endearing towns feature some of Romania's friendliest locals. Beyond the hinterland, Moldavian modernity is fully displayed in Iaşi, one of Romania's largest cities and a vibrant student town famous for its nightlife. Bucovina, to the northwest, is home to Romania's pride and joy: a half dozen Unesco-protected painted monasteries from the 15th and 16th centuries that attest to the region's artistic skills and enduring faith. Everywhere you'll find signs of Moldavian prince (and Romanian national hero) Ștefan cel Mare and his epic battles with the Ottoman Empire, above all at the mighty fortresses at Suceava and Târgu Neamţ.
Jump to:Table of contents
Must see experiences
These are our favorite local haunts, touristy spots, and hidden gems throughout Moldavia & the Bucovina Monasteries.
Discover more sights
Voroneţ Monastery
Built in just three months and three weeks by Ştefan cel Mare following a key 1488 victory over the Turks, Voroneţ Monastery is the only painted monastery that has had an internationally recognised colour associated with it. 'Voroneţ Blue', a vibrant cerulean hue created from lapis lazuli and other ingredients, is prominent in its frescoes. A 2011 restoration of frescoes in the entryway revealed the incredible quality of these paintings even more clearly.
Palace of Culture
Iaşi's premier attraction and symbol of the city is the grandiose Gothic-revival Palace of Culture that dominates the horizon at the southern end of B-dul Ştefan cel Mare şi Sfânt. Though it looks as if it stepped out of a medieval fairy tale, the building is only around 100 years old (built from 1906 to 1925). The palace stands over Prince Alexandru cel Bun's ruined 15th-century princely court. Visitors can tour the palace, climb the tower and explore four major museums.
Arbore Monastery
This Unesco-protected church in the village of Arbore receives a fraction of the visitors of the other painted monasteries and hence feels more private and special. The small scale allows you to study the paintings up close, to appreciate the skills and techniques. The monastery dates from 1503 and was the brainchild of local nobleman Luca Arbore. It took about five months to build and four decades to paint.
Suceviţa Monastery
Suceviţa Monastery (built 1582–1601) is the largest Bucovina monastery, and some regard it as the finest. It's perhaps best known for its exterior Ladder of Virtues fresco, with its 32 steps to heaven, near the main entry. It exhorts priests to righteous behaviour and to avoid the unfortunate fate of the clerics depicted tumbling from the ladder due to sins such as greed or vanity. The church's tomb room contains the coffins of monastery founders Simion and Ieremia Movilă.
Royal Citadel
Suceava's rugged, abandoned 14th-century citadel has gotten a high-tech makeover, allowing visitors to scramble over the rocks and into the various chambers and learn the structure's history through clever video presentations and hands-on touchscreen exhibits. It's great for kids, the only downside being most of the text and video is only in Romanian. The unconquerable fortress withstood multiple attacks, including one by Ottoman Sultan Mehmed II in 1475, just 22 years after his conquest of Constantinople (Istanbul).
Agapia Monastery
Agapia Monastery is an active nunnery, housing 300 to 400 nuns in two locations. The main monastery, Agapia din Vale, stands at the western end of Agapia village. It was built in 1644 by Gavril Coci (Vasile Lupu's brother). It has relaxing gardens and an impressive facade, but most come to see the interior frescoes painted from 1858-61 by Romanian master Nicolae Grigorescu. A second, smaller monastery, Agapia din Deal (sometimes called Agapia Veche), is 1.6km up a steep road.
Moldoviţa Monastery
Built in 1532, Moldoviţa Monastery occupies a fortified quadrangular enclosure with tower, gates and well-tended lawns. The central painted church has been partly restored and features impressive frescoes from 1537. The southern exterior wall depicts the siege of Constantinople in AD 626, under a combined Persian-Avar attack. Interestingly, the besiegers are depicted in Turkish dress – keeping parishioners concentrated on the contemporary enemy.
Golia Monastery
This beautiful late Renaissance–style monastery is guarded by thick walls and the 30m-high Golia tower, which you can climb (120 steps) for views out over the city. The 17th-century church is notable for its vibrant Byzantine frescoes and intricately carved doorways, and features bastions from 1667. The complex also contains a small museum dedicated to writer and one-time resident Ion Creangă (1837–89), renowned for his Moldavian folklore–inspired short stories.
Neamţ Citadel
Medieval Neamţ Citadel had already long been considered Moldavia's finest fortress before recent renovations improved it again. It was built in 1359 by Moldavian Prince Petru I Muşat, who picked an impregnable high location. The castle successfully resisted attacks by Hungarians in 1395 and by Turks in 1476, and was only conquered by Polish forces in 1691. The citadel is 2km west of the centre, following the main road B-dul Ştefan cel Mare. It's a 15-minute scramble to the top.
More sights
Whether it's a guided tour of a historic landmark, private tasting of local delicacies, or an off-road adventure — explore the best experiences in Moldavia & the Bucovina Monasteries.
Discover more activities
Private adventure day trip from Iasi
Private day trip from Iasi to the UNESCO Painted Monasteries in Bucovina
Private Iasi City Tour
For Explorers Everywhere
Get 20% off our online shop.
I want emails from Lonely Planet with travel and product information, promotions, advertisements, third-party offers, and surveys. I can unsubscribe any time using the unsubscribe link at the end of all emails. Contact Lonely Planet or view our Privacy Policy.


I'm based on the north side of Brisbane and specialise in baby photography. I had the pleasure of Master L visiting my studio the other day. So special. 6 weeks old | 2 days adjusted by due date. His family also came along with his furry friend Yoda the pug dog.


Gerry Judah has bestowed another form of cars-flying-in-the-sky sculpture unto humanity, this time at the request of Porsche GB. He's well known for this sort of metal aerobics, like a collection of airplanes and their contrails frozen in time – of course fashioned for a decidedly automotive flavor. I dig it.
Artist and designer Gerry Judah has created a gravity-defying sculpture that holds three iconic Porsche sports cars 35 metres high in the sky. The sculpture was the centrepiece at the recent Goodwood Festival of Speed in West Sussex, England.
Judah was commissioned by Porsche GB to create the sculpture as a celebration of 50 years of the Porsche 911. The sculpture has three futuristic white, steel arrows that race upwards, each with an example of the 911 at its apex. The models incorporated in the sculpture are: the 1963 Original 911; the 1973 911 Carrera RS 2.7; and the 2013 911.
"Simple, pure and built for the job." Porsche enthusiasts the world over, rejoice; a sculptor somewhere on this earth understands your plight.


text:
package org.hl7.v3;

import javax.xml.bind.annotation.XmlEnum;
import javax.xml.bind.annotation.XmlType;

/**
 *
Java class for InjectionMedicalDevice.
 *
 *
The following schema fragment specifies the expected content contained within this class.
 *

 *

 * <simpleType name="InjectionMedicalDevice">
 *   <restriction base="{urn:hl7-org:v3}cs">
 *     <enumeration value="AINJ"/>
 *     <enumeration value="PEN"/>
 *     <enumeration value="SYR"/>
 *   </restriction>
 * </simpleType>
 *

 *
 */
@XmlType(name = "InjectionMedicalDevice")
@XmlEnum
public enum InjectionMedicalDevice {

    AINJ,
    PEN,
    SYR;

    public String value() {
        return name();
    }

    public static InjectionMedicalDevice fromValue(String v) {
        return valueOf(v);
    }

}


Dr. Zhang's research interests span the fields of Data Fusion, Data Mining, and Machine Learning. The research projects in IFM Lab directed by Dr. Zhang include knowledge discovery from online social networks, text data, knowledge graphs, enterprise context data, human brain images with traditional machine learning and deep learning techniques. His research works focus on fusing multiple large-scale information sources of diverse varieties together, and carrying out synergistic data mining tasks across these fused sources in one unified analytic.


text:
Omar for detailed probe into infant deaths at Srinagar hospital
J&K chief minister Omar Abdullah said the report on high infant mortality at the Valley's only paediatric hospital will be sent to the State Vigilance Organisation and State Accountability Commission to fix responsibility in the matter.
chandigarh Updated: Aug 02, 2012 19:14 IST
Jammu and Kashmir chief minister Omar Abdullah on Wednesday said the report on high infant mortality at the Valley's only paediatric hospital will be sent to the State Vigilance Organisation and State Accountability Commission to fix responsibility in the matter.
"I believe this report needs to form the (basis of) inquiry both by the vigilance and the accountability commission. I believe responsibility needs to be fixed. The report submitted by director Sher-i-Kashmir Institute of Medical Sciences (SKIMS) was not to fix the responsibility," Omar said
In May, the state government had ordered an inquiry by director SKIMS Dr Showkat Zargar to probe the high number of infant deaths at the GB Pant hospital.
More than 500 infants, mostly neonates, have died this year at the hospital, which led to a public outcry. The then medical superintendent of the hospital Javed Chaowdhury was attached pending an inquiry.
Abdullah said, he has not cleared anyone of the responsibility for the situation the hospital was in.
"There is no denying of the failure at multiple levels, right from the hospital to the secretariat, resulted in the situation. I myself had to step in, and between myself and officers with me, we put in place certain corrective measures wherein the situation has been addressed to a large extent," he said.
The doctors who have deposed before the inquiry officer have alleged that they were forced to prescribe medicines from sub-standard companies and anyone who refused to follow the instructions of the hospital administration was humiliated.
The authorities have sealed a medical shop inside the hospital premises following the report of Dr Zargar.
"It is known that people from lesser known drug companies were operating through this shop and were moving about in the hospital. The employees of the shop were also trying to promote drugs in the hospital and such things cannot thrive without a nexus," said medical superintendent of GB Pant hospital Dr Muneer Masoodi.
First Published: Aug 02, 2012 16:34 IST


text:
Q: How to override CSS of ngbPopover in angular 5? I'm using ng-bootstrap and want to add custom CSS for popover content.
I'm trying to apply in app.component.css but it is not applying in popover-body.

A: You can use ViewEncapsulation.None. This mean that "the style is wrapped in a style tag and pushed to the head"
@Component({
  selector: 'my-app',
  template: `
...  `,
  styles:[`.popover-title{background-color:black;color:white}`],
  encapsulation: ViewEncapsulation.None
})

A: Try this to override the style
//component.css
::ng-deep .popover-body {
 background-color:black;
 color:white;
}

A: No, ViewEncapsulation.None can be added if you use a stylesUrl too. If you want that ViewEncapsutaion don't affected to the rest of the app, your styles can be like .custom .popover-title {...} and enclosed your ngPopover into < div class="custom">...< /div>
//component.css
.custom .popover-title
{
     background-color:black;color:white
}

//component.html
<div class="custom">
   <button type="button" class="btn btn-outline-secondary" placement="top"
        ngbPopover="Vivamus sagittis lacus vel augue laoreet rutrum faucibus." popoverTitle="Popover on top">
  Popover on top
   </button>
</div>

If that's not work always can "simulated" a popover like
//in your component.ts add a variable
//customtooltip:boolean=false;
<div [ngbCollapse]="!customtooltip" class="custom-tooltip">
    show me something
</div>
<button (mouseover)="customtooltip=true" (mouseleave)="customtooltip=false">pass over the mouse</button>

redpajama_set_name: RedPajamaStackExchange


Introducing 'The Amulet', Personalized Children's Novel!
Click here for a PDF of the entire press release.
London, Ontario, Canada - November 22, 2005: Book By You® today announced the release of its latest full-length personalized children's novel, The Amulet. Book By You® is the only company in the world to offer full-length personalized children's novels. This new novel is the third in their series adapted from Edith Nesbit's classics.
Adults and children co-author The Amulet by selecting the names, physical features and places to personalize in this 130-page, professionally bound paperback. With over 20 features to personalize, children can put themselves in the leading role and include friends, relatives or even their favorite TV characters! The character questionnaire, available on the Book By You® website, is fun and easy to complete with three essential characters and features such as hair color and length, eye color, age and address - even include a pet. The Amulet's many personalized characteristics make this book a remarkably individual and unique gift that motivates children to read. To add the finishing touch, The Amulet is beautifully bound with a personalized front cover.
This adaptation of noted author Edith Nesbit's text from a century ago brings an up-to-date flavor to the children's exploits. The Amulet is the sequel to Two Children and It, which is a personalized adaptation of the Nesbit classic and now a movie titled, Five Children and It. This storyline introduced readers to a mysterious sand-fairy creature called a Psammead that grants wishes. In The Amulet, the Psammead joins the children on a journey across a magical back-drop in a search for their favorite and beloved lost pet. The children are guided by an ancient amulet and words of wisdom from the Psammead. Traveling through time, the youngsters experience a number of exploits first hand. They make friends with an Egyptian, introduce a sea captain to a compass, and help place a major archeological find in a museum.
This book is ideal for children of reading age or can be read to younger children as a bedtime story. Themes such as the value of friendship, perseverance and following your dreams are explored and uniquely presented in a manner only possible through a full-length book format.
The Amulet can be purchased for $24.95. For more details and a free personalized preview visit the company's website at www.BookByYou.com. Click here for a PDF of the entire press release.